Successful Treatment of Iron-Overload Cardiomyopathy in Hereditary Hemochromatosis With Deferoxamine and Deferiprone
Language English Country Great Britain, England Media print-electronic
Document type Case Reports, Journal Article
PubMed
27789107
DOI
10.1016/j.cjca.2016.07.589
PII: S0828-282X(16)30811-X
Knihovny.cz E-resources
- MeSH
- Iron Chelating Agents administration & dosage MeSH
- Deferiprone MeSH
- Deferoxamine administration & dosage MeSH
- Ventricular Dysfunction, Left diagnosis etiology MeSH
- Ferritins analysis MeSH
- Hemochromatosis * blood diagnosis drug therapy physiopathology MeSH
- Cardiomyopathies * diagnosis etiology physiopathology therapy MeSH
- Middle Aged MeSH
- Humans MeSH
- Magnetic Resonance Imaging, Cine methods MeSH
- Liver Diseases diagnosis etiology MeSH
- Iron Overload blood complications MeSH
- Hemochromatosis Protein genetics MeSH
- Pyridones administration & dosage MeSH
- Heart Failure * diagnosis drug therapy etiology MeSH
- Severity of Illness Index MeSH
- Stroke Volume MeSH
- Transferrin analysis MeSH
- Treatment Outcome MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
- Names of Substances
- Iron Chelating Agents MeSH
- Deferiprone MeSH
- Deferoxamine MeSH
- Ferritins MeSH
- HFE protein, human MeSH Browser
- Hemochromatosis Protein MeSH
- Pyridones MeSH
- Transferrin MeSH
There is scarce evidence regarding the use of iron chelators in patients with hereditary hemochromatosis who are intolerant of phlebotomy or erythrocytapheresis. A 52-year-old man with genetically confirmed HFE hemochromatosis presented with liver disease and heart failure with severe left ventricular systolic dysfunction. Because of anemia after initial treatment, we added intravenous deferoxamine followed by oral deferiprone to less frequent erythrocytapheresis, which normalized systolic function within 1 year. Repeated cardiac magnetic resonance imaging revealed improvement of the T2* relaxation time. This report illustrates the beneficial effect of iron chelators in individuals with HFE hemochromatosis and poor tolerance of erythrocytapheresis.
Department of Cardiology IKEM Prague Czech Republic
Department of Hepatogastroenterology IKEM Prague Czech Republic
References provided by Crossref.org
